Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.96M | -26.22M | -25.50M | -28.22M | -27.00M |
| Total Depreciation and Amortization | 194.20K | 180.80K | 171.70K | 158.40K | 159.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.63M | 3.90M | 2.10M | -107.20K | -2.11M |
| Change in Net Operating Assets | -6.35M | -7.72M | -6.76M | -1.82M | 3.21M |
| Cash from Operations | -30.48M | -29.86M | -29.99M | -29.99M | -25.74M |
| Capital Expenditure | -421.80K | -266.40K | -104.20K | -109.30K | -76.60K |
| Sale of Property, Plant, and Equipment | 600.00 | 29.10K | 29.10K | 28.50K | 28.50K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -421.30K | -237.40K | -75.20K | -80.80K | -48.10K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -4.60M | -9.12M | -9.14M | -9.16M | -4.58M |
| Issuance of Common Stock | 32.40M | 32.16M | 54.92M | 23.22M | 39.52M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 27.80M | 23.04M | 45.78M | 14.06M | 34.95M |
| Foreign Exchange rate Adjustments | -448.40K | -1.40M | -1.96M | 107.00K | -264.60K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.55M | -8.45M | 13.76M | -15.90M | 8.89M |